This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pharmaceuticals: Archive
Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates
by Zacks Equity Research
SRPT posts a wider Q4 loss as Elevidys sales tumble, but revenues top estimates and 2026 guidance outlines a cautious recovery path.
RHHBYPositive Net Change SRPTNegative Net Change ARWRNegative Net Change
biotechs gene-editing gene-therapy medical pharmaceuticals
Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y
by Zacks Equity Research
CPRX tops Q4 estimates as Firdapse and Agamree sales jump, lifting 2025 results and driving upbeat 2026 revenue guidance.
CPRXNegative Net Change USNAPositive Net Change CSTLNegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
ACAD Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth
by Zacks Equity Research
Acadia beats Q4 EPS estimates as Nuplazid and Daybue lift revenues 9%, but sales miss and EU setback cloud trofinetide outlook with 2026 sales at $1.22-$1.28 billion.
USNAPositive Net Change ACADNegative Net Change CSTLNegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View
by Zacks Equity Research
Revolution Medicines posts a wider-than-expected Q4 loss and sees 2026 operating expenses of $1.6B-$1.7B as it advances late-stage RAS pipeline studies.
BMYPositive Net Change SMMTPositive Net Change RVMDNegative Net Change TNGXNegative Net Change
biotechs earnings medical pharmaceuticals
Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook
by Zacks Equity Research
IONS beats Q4 estimates on strong Tryngolza sales, but shares slip 5% as 2026 revenue outlook and slower uptake for new drugs weigh on sentiment.
AZNPositive Net Change GSKPositive Net Change BIIBPositive Net Change IONSPositive Net Change
pharmaceuticals
CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans
by Zacks Equity Research
CYTK reports a wider-than-expected Q4 loss as expenses rise, but Myqorzo wins FDA nod and global expansion advances, with $1.22B cash fueling 2026 catalysts.
SNYPositive Net Change BMYPositive Net Change BAYRYNegative Net Change CYTKNegative Net Change
biotechnology biotechs medical pharmaceuticals
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up
by Zacks Equity Research
Recursion Pharmaceuticals stock up on narrower Q4 loss as revenues jump on Roche milestone, beating estimates and boosting cash runway into 2028.
CSTLNegative Net Change HRMYNegative Net Change IMCRPositive Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
The Zacks Analyst Blog Highlights Costco Wholesale, Roche, Lam Research, Spruce Power and IDT
by Zacks Equity Research
Costco, Roche and Lam Research lead Zacks??? top stock reports, with standout gains and resilient fundamentals across sectors.
RHHBYPositive Net Change LRCXNegative Net Change COSTPositive Net Change IDTPositive Net Change SPRUNegative Net Change
computers pharmaceuticals retail semiconductor utilities
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y
by Zacks Equity Research
APLS posts wider-than-expected Q4 loss as Syfovre sales slip 8%, but revenues top estimates and Empaveli surges 50% on a strong new indication launch.
APLSNegative Net Change CSTLNegative Net Change HRMYNegative Net Change IMCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Can J&J Sustain Its Double-Digit Oncology Growth Streak?
by Kinjel Shah
JNJ's oncology sales surged in 2025 as Darzalex and new drugs powered growth. With a $50B target by 2030, can its cancer momentum last?
AZNPositive Net Change JNJPositive Net Change PFEPositive Net Change MRKPositive Net Change
pharmaceuticals